Row Threatens EU-Israel Research

The European Union’s declaration that it will not support research in Israel’s occupied territories may prompt the country to forgo participation in the Horizon 2020 program.

Written byChris Palmer
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

A barrier wall in the West BankWIKIMEDIA, SOMANNew European Commission guidelines issued on July 19 stipulate that as of 2014, EU research funds will not support projects in areas that were not under Israel’s control before 1967, including the occupied West Bank, East Jerusalem, the Gaza Strip, and the Golan Heights. In response, Israel is considering dropping out of Horizon 2020, a lucrative European Union research program that had been expected to bolster Israel’s research coffers by about €300 million ($401 million). Negotiations on the wording of the guidelines will continue in Brussels in September.

European Commission spokesperson Michael Jennings told ScienceInsider that the European Union’s ban on funding projects in the occupied territories amounts to a clarification of a preexisting policy, and that the impact will be minimal, because little research is done there. However, the guidelines are being considered by Israeli officials to be an affront to their national sovereignty. “We will not accept any outside diktat about our borders,” Prime Minister Benjamin Netanyahu said in a statement last month.

Israel, home to a fast-growing biotech industry, has participated in EU research programs since 1996 as an “associated country”—a status that allows countries outside of the European Union to compete for research grants in exchange for a fixed cut of the country’s gross domestic project. During the most ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies